Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Role of Circulating Tumor Cells in Patients with Pancreatic Cancer: a Meta-analysis

  • Ma, Xue-Lei (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Li, Yan-Yan (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Zhang, Jing (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Huang, Jing-Wen (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Jia, Hong-Yuan (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Liu, Lei (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) ;
  • Li, Ping (Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Isolation and characterization of circulating tumor cells (CTCs) in patients suffering from a variety of different cancers have become hot biomarker topics. In this study, we evaluated the prognostic value of CTCs in pancreatic cancer. Materials and Methods: Initial literature was identified using Medline and EMBASE. The primary data were hazard ratios (HRs) with 95% confidence intervals (CIs) of survival outcomes, including overall survival (OS) and progression free survival/recurrence free survival (PFS/RFS). Results: A total of 9 eligible studies were included in this meta-analysis, published between 2002 and 2013. The estimated pooled HR and 95%CI for OS for all studies was 1.64 (95%CI 1.39-1.94, p<0.00001) and the pooled HR and 95%CI for RFS/DFS was 2.36 (95%CI 1.41-3.96, p<0.00001). The HRs and 95%CIs for OS and RFS/DFS in patients before treatment were 1.93 (95%CI 1.26-2.96, p=0.003) and 1.82 (95%CI 1.22-2.72, p=0.003), respectively. In patients receiving treatment, the HRs and 95%CI for OS and RFS/DFS were 1.37 (95%CI 1.00-1.86, p=0.05) and 1.89 (95%CI 1.01-3.51, p=0.05), respectively. Moreover, the pooled HR and 95%CI for OS in the post-treatment group was 2.20 (95%CI 0.80-6.02, p=0.13) and the pooled HR for RFS/DFS was 8.36 (95%CI 3.22-21.67, p<0.0001). Conclusions: The meta-analysis provided strong evidence supporting the proposition that CTCs detected in peripheral blood have a fine predictive role in pancreatic patients especially on the time point of post-treatment.

Keywords

References

  1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50 , 1088-101. https://doi.org/10.2307/2533446
  2. Bidard FC, Huguet F, Louvet C, et al (2013). Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol, 24, 2057-61. https://doi.org/10.1093/annonc/mdt176
  3. Cen P, Ni X, Yang J, et al (2012). Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta, 1826, 350-6.
  4. Cohen SJ, Punt CJ, Iannotti N, et al (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 26, 3213-21. https://doi.org/10.1200/JCO.2007.15.8923
  5. Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351, 781-91. https://doi.org/10.1056/NEJMoa040766
  6. de Albuquerque A, Kubisch I, Breier G, et al (2012). Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study, Oncology, 82, 3-10. https://doi.org/10.1159/000335479
  7. Dong X, Alpaugh KR, Cristofanilli M (2012). Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res, 24, 388-98. https://doi.org/10.1007/s11670-012-0279-4
  8. Ghaneh P, Costello E, Neoptolemos JP (2008). Biology and management of pancreatic cancer. Postgrad Med J, 84, 478-97. https://doi.org/10.1136/gut.2006.103333
  9. Goodman OB, Jr Symanowski JT, Loudyi A, et al (2011). Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer, 9, 31-8. https://doi.org/10.1016/j.clgc.2011.04.001
  10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  11. Hiltermann TJ, Pore MM, van den Berg, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42. https://doi.org/10.1093/annonc/mds138
  12. Hofman V, Ilie MI, Long E, et al (2011). Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer, 129, 1651-60. https://doi.org/10.1002/ijc.25819
  13. Khoja L, Backen A, Sloane R, et al (2012). A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer, 106, 508-16. https://doi.org/10.1038/bjc.2011.545
  14. Kokhanenko, NIu, Ignashov AM, et al (2001). Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol, 47, 294-7.
  15. Kowalewska M, Chechlinska M, Markowicz S, et al (2006). The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer, 42, 2671-4. https://doi.org/10.1016/j.ejca.2006.05.036
  16. Kurihara T, Itoi T, Sofuni A, et al (2008). Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg, 15, 189-95. https://doi.org/10.1007/s00534-007-1250-5
  17. Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44. https://doi.org/10.7314/APJCP.2012.13.4.1137
  18. Mataki Y, Takao S, Maemura K, et al (2004). Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during followup period of patients who underwent curative surgery for biliary-pancreatic cancer: longitudinal analyses. Clin Cancer Res, 10, 3807-14. https://doi.org/10.1158/1078-0432.CCR-03-0130
  19. Muller P, Schlimok G (2000). Bone marrow “micrometastases” of epithelial tumors: detection and clinical relevance. J Cancer Res Clin Oncol, 126, 607-18. https://doi.org/10.1007/PL00008472
  20. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  21. Sergeant G, Roskams T, van Pelt J, et al (2011). Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer, 11, 47. https://doi.org/10.1186/1471-2407-11-47
  22. Sergeant G, van Eijsden R, Roskams T, et al (2012). Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer, 12, 527. https://doi.org/10.1186/1471-2407-12-527
  23. Soeth E, Grigoleit U, Moellmann B, et al (2005). Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol, 131, 669-76. https://doi.org/10.1007/s00432-005-0008-1
  24. Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9. https://doi.org/10.7314/APJCP.2013.14.3.1725
  25. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  26. Tjensvoll K, Nordgard O, Smaaland R (2013). Circulating tumor cells in pancreatic cancer patients: Methods of detection and clinical implications, Int J Cancer, 8, 16.
  27. Uchikura K, Takao S, Nakajo A, et al (2002). Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol, 9, 364-70. https://doi.org/10.1007/BF02573871
  28. Uen YH, Lu CY, Tsai HL, et al (2008). Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol, 15, 2120-8. https://doi.org/10.1245/s10434-008-9961-7
  29. Wang FB, Yang XQ, Yang S, et al (2011). A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35.
  30. Williamson PR, Smith CT, Hutton JL, et al (2002). Aggregate data meta-analysis with time-to-event outcomes, Stat Med, 21, 3337-51. https://doi.org/10.1002/sim.1303
  31. Zhou J, Hu L, Yu Z, et al (2011). Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res, 171, 631-6. https://doi.org/10.1016/j.jss.2010.05.007
  32. Zippelius A, Pantel K (2000). RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci, 906, 110-23.

Cited by

  1. Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps vol.15, pp.10, 2015, https://doi.org/10.1039/C5LC00226E
  2. Liquid biopsy vol.27, pp.6, 2015, https://doi.org/10.1097/CCO.0000000000000223
  3. Clinicopathological and Prognostic Significance of Circulating Tumor Cells in Patients with Head and Neck Cancer: A Meta-Analysis vol.05, pp.02, 2016, https://doi.org/10.4236/ijmpcero.2016.52015
  4. Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes? vol.41, pp.2, 2017, https://doi.org/10.1159/000458736
  5. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial pp.1573-0646, 2018, https://doi.org/10.1007/s10637-018-0639-0